Management - an experienced and inter-disciplinary team


Mr. Oliver Schacht, a corporate finance professional and expert in the molecular diagnostics industry, has been CEO of Curetis since April 2011 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 to end of the first quarter in 2011. He was a co-founder and CFO of Epigenomics AG (Berlin, Germany) and the CEO of Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two IPOs), as well as corporate finance, investor relations, PR, marketing and business development. Mr. Schacht also serves on the Board of BIO Deutschland e.V. as treasurer and on the Supervisory Board of Protagen AG (Dortmund, Germany). Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master’s degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999, he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries. He has co-founded several start-up companies in biotech, IT and education in Europe and the USA.

Johannes Bacher – COO

Johannes Bacher combines over 20 years of R&D and managerial experience with extensive expertise in research & development, clinical trials, international project management, finance, human resources and legal affairs. Hence, the Curetis co-founder is ideally suited to managing the general R&D and Clinical Trial operations of Curetis. Johannes has a degree in electrical engineering and has already worked for several international medical technology companies, including Hewlett Packard, Agilent and Philips Medical Systems.

Dr. Achim Plum – CBO

Dr. Achim Plum joined the Curetis Management Board in 2015. As Chief Business Officer, Dr. Plum drives corporate and business development of the Curetis Group. Further, his responsibilities include corporate communications, legal, and human resources. Since its incorporation in 2017, Dr. Plum is also one of the managing directors of Ares Genetics GmbH in Vienna, Austria, a new company of the Curetis Group. Before joining Curetis in 2015, Dr. Plum had the global responsibility for the Area Diagnostics and Biosciences Research in the Technology Center of Siemens Healthcare, now Siemens Healthineers. Before Siemens, Dr. Plum worked for eight years at the publicly listed German-American molecular diagnostics company Epigenomics AG, lastly as Senior Vice President Business & Strategy. After undergraduate and postgraduate studies in genetics, cell biology, and biochemistry at the University of Bonn (Germany) and the University of East Anglia (Norwich, UK), Dr. Plum received his PhD from the University of Bonn in 1999 for research into novel genetic models of human diseases.

Andreas Boos – CTO

Andreas Boos – CTO

With over 25 years of professional experience at Hewlett Packard, Agilent and Philips, Curetis co-founder Andreas Boos boasts a wealth of international experience in developing and implementing solutions for patient monitoring and on-site molecular diagnostics. As a graduate electrical engineer, Andreas Boos has successfully applied his project management skills to lead the development of several innovative and commercially successful medical devices for the global markets. In addition to his extensive knowledge of customer requirements, Andreas brings to Curetis a comprehensive understanding of quality systems, standards and global regulatory approval procedures.

Christopher Emery – President & CEO Curetis USA, Inc.

Chris Emery has joined Curetis as President and CEO of Curetis USA, Inc., bringing more than 20 years of healthcare experience and 10 years in executive leadership roles in the laboratory diagnostics, medical device and pharmaceuticals industries. Chris' primary focus has been leading the commercial launch and execution for numerous next-generation molecular diagnostic assays in the precision medicine market. Most recently, he was the Chief Commercial Officer – North America for Menarini Silicon Biosystems, where he directed the U.S. sales and business development activities for the DEPArray NxT molecular device as well as the integration of the FDA-cleared CellSearch Circulating Tumor Cell assay. Prior, Chris was the General Manager for Abbott's PersonalizeDx cancer diagnostics laboratory division, and he also held senior level management roles as Chief Operating Officer at CombiMatrix, VP Sales & Marketing at Response Genetics, and National Sales & Marketing Manager at US LABS, prior to its acquisition by LabCorp. Chris began his career in healthcare with Johnson & Johnson, promoting the antibiotic Levaquin into hospital systems for a wide variety of bacterial infections, including hospital-acquired pneumonia. He obtained his MBA from Pepperdine University and his BA in Communications Studies from University of California - San Diego.

Heiko Schorr – Director Finance

Heiko Schorr has worked for Curetis as Director Finance since March 2012. He has nearly 20 years of professional experience in various roles with increasing managerial responsibility in the fields of accounting, taxes, finances and controlling. In his career to date, Heiko Schorr has already established and managed teams of employees in large corporations and in medium-sized high-tech companies. He has introduced ERP systems (Navision) as well as budgeting and reporting systems for various locations and international offices. Heiko has extensive specialist expertise thanks to his previous positions as Head of Finance & Controlling at Betec Electronic GmbH and as Intercompany Accountant at Yves Rocher GmbH. Heiko Schorr has a degree (IFRS economist) from Nürtingen University of Applied Sciences, is a certified accountant (Reutlingen Chamber of Commerce) and completed training to become a tax consultant at Stuttgart Chamber of Tax Consultants.

Riwat Lim - Director Commercial Operations EMEA

Riwat Lim is Director of Commercial Operations EMEA of Curetis.
Riwat joined from QIAGEN where he led a Market Development Team across Northern Europe and drove double digit growth for the TB testing portfolio. While there he also developed strategic working partnerships with distributors and private reference laboratories. He started his career in healthcare working for pharmaceutical companies including Pfizer and Procter & Gamble where he gained experience in Sales, Marketing and Management. He initiated and designed national patient screening services and patient support programs, which are now commissioned by government healthcare authorities. He graduated with a Masters in Economics and Business Administration from Nice University in France. Riwat brings to Curetis his 18 years of passion for patient care and expertise in driving commercial success.

Dr. Helmut Hilbert – Head of Business Development

Dr. Helmut Hilbert has been working for Curetis as Head of Business Development since 2013. Prior to this position, he was employed by Qiagen as Associate Director of Corporate Business Development. In addition to seven years of R&D activities, Dr. Helmut Hilbert has more than ten years' experience in business and corporate development, and has an impressive track record in the fields of licensing, mergers & acquisitions, technology transfer and innovation management. At Qiagen, Helmut was responsible for assessing new technologies and evaluating acquisition candidates and investment opportunities. His responsibilities also included contract negotiations, due diligence and the integration of acquired companies and technologies.


Andreas Posch has joined Curetis as Director GEAR &  BioIT in 2017. He joined from Siemens, where he was responsible for BioIT R&D at Siemens Healthcare as well as Software Sensors & Analytics with Siemens Corporate Technology. As designated Principal Key Expert for Bioinformatics & Systems Medicine at Siemens Healthcare, he developed, executed and directed global innovation and R&D projects focusing on next-generation sequencing for diagnostic purposes, biomarker discovery, multi-scale disease modeling, advanced clinical decision support as well as genetic antibiotic resistance testing (GEAR). He has an academic background in bioinformatics and biotechnology and his Ph.D. within the “Applied Bioscience Technology” program at the Vienna University of Technology was recognized by international awards while the industrial relevance of his thesis resulted in several million Euro funding from industry and competitive research grants.

Bernd Bleile, Ass.iur. - General Counsel

Bernd Bleile has joined Curetis as General Counsel in February 2016. He is responsible for all legal affairs within Curetis, including general legal advice, workshops and trainings on legal topics, contract preparation and review, foundation and legal support of subsidiaries, contact for external lawyers, to appear in court etc. Prior to Curetis, he worked in the area of law at “SMARTRAC”, a leading RFID product developing and manufacturing company, and at a former subsidiary of Daimler “MercedesBenz Technologies” in Sindelfingen. He qualified as a lawyer and graduated as Master of Public Management (Dipl. Verwaltungswirt/FHöV - Rentenversicherung) at the University of Tübingen, University of Applied Sciences Ludwigsburg and German Federal Pension Fund Baden-Württemberg. In addition, he qualified as in-house data protection officer at TÜV-Süd.

Dr. Michael Schleichert - Director IVD Development

Dr. Michael Schleichert joined Curetis as Director IVD Development in 2017. Previously, he was responsible for the development of several molecular assays and automation systems in the field of HPV (human papilloma virus) and the lead of several teams in the IVD division at Greiner Bio-One Diagnostics. He has over 10 years experience in molecular diagnostics and IVD product development. Dr. Michael Schleichert obtained a Ph.D. in molecular biology at the University Freiburg and studied biology at the University Bayreuth.

Dr. Gerd Luedke – Director Innovation, Technology & IP

Dr. Gerd Luedke is able to look back on a twenty-year career in the field of assay development for research and for analytical and diagnostic systems. He has experience in heading up international projects in multiple locations. He has been responsible for the design of molecular diagnostic assays and the development of clinical applications. Prior to co-founding Curetis, Gerd had worked as a project manager for microfluidics systems at Agilent Technologies as well as for test development at Philips Medical Systems. Dr. Gerd Luedke obtained a doctorate in lung cancer tumor biology at Zurich University Hospital and studied Technical Biology at the University of Stuttgart.